Sintesis, Karakterisasi Struktur, dan Kajian Molecular Docking Senyawa Turunan 4’-Metoksi Flavonol sebagai Antagonis Reseptor Estrogen Alpha (ER-a) pada Kanker Payudara
DOI:
https://doi.org/10.25077/jrk.v13i2.553Keywords:
chlorinated flavonol, docking study, estrogen receptor, breast cancer, Methoxy flavonol;Abstract
A long period of drug administration in breast cancer chemotherapy can cause various side effects. These situations encourage researchers to search for and develop alternative anticancer drugs through various approaches. This study aimed to synthesize a flavonol derivative (TF4) and to study the interactions of the synthesized compound with ER-α as one of the targeted receptors in breast cancer treatment. The synthesis was carried out using the stirring method and the study of interactions of TF4 with ER-α was performed through molecular docking against ER-α crystal structures bound to an antagonist (PDB ID: 3ERT) and agonist (PDB ID: 1A52). The synthesis of TF4 produced crude product in 58 % yield and pure product in 6 % yield. The structure of TF4 was confirmed by spectroscopic analyses including UV, FT-IR, 1D, and 2D NMR. The docking results showed that the TF4 does not form any conventional hydrogen bond with ER-α. However, it can form carbon-hydrogen (C--H) bonds and van der Walls interactions with several important residues on the active site of ER-α. In addition, the binding free energy values of TF4 (-9.14 and -9.50 kcal/mol) are more negative than estradiol (E2) as one of the natural ligands for ER-α. Thus, it can be estimated that TF4 can be bounded easier on the active site of ER-α than its natural ligand. It may presume that it can act as an estrogen antagonist because of the similarity in interactions and binding poses compared to TAM, TOR, dan 4-OHT as reference drug molecules.
References
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. & Bray, F., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin., 71(3): 209–249 (2021).
Kemkes RI., Hari Kanker Sedunia 2019.
Yudissanta, A. & Ratna, M., Analisis pemakaian kemoterapi pada kasus kanker payudara dengan menggunakan metode regresi logistik multinomial (studi kasus pasien di Rumah Sakit “X” Surabaya). J. Sains dan Seni ITS, 1(1): D112–D117 (2012).
KemkesRI., Panduan Penatalaksanaan Kanker Payudara. Komite Penanggulangan Kanker Nasional, (2015).
Riggs, B. L. & Hartmann, L. C., Selective Estrogen-Receptor Modulators -Mechanisms of Action and Application to Clinical Practice. N. Engl. J. Med., 348(7): 618–629 (2003).
Roelfsema, F., Yang, R. J., Takahashi, P. Y., Erickson, D., Bowers, C. Y. & Veldhuis, J. D., Effects of toremifene, a selective estrogen receptor modulator, on spontaneous and stimulated GH secretion, IGF-I, and IGF-binding proteins in healthy elderly subjects. J. Endocr. Soc., 2(2): 154–165 (2018).
Fujimura, T., Takahashi, S., Kume, H., Urano, T., Takayama, K., Yamada, Y., Suzuki, M., et al., Toremifene, a Selective Estrogen Receptor Modulator, Significantly Improved Biochemical Recurrence in Bone Metastatic Prostate Cancer: a Randomized Controlled Phase II a Trial. BMC Cancer, 15(1): 836 (2015).
Mirkin, S. & Pickar, J. H., Selective estrogen receptor modulators (SERMs): A review of clinical data. Maturitas, 80(1): 52–57 (2015).
Hayashi, S. I., Eguchi, H., Tanimoto, K., Yoshida, T., Omoto, Y., Inoue, A., Yosida, N., et al., The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr. Relat. Cancer, 10(2): 193–202 (2003).
Gunawan, S. G., Farmakologi dan Terapi. Fakultas Kedokteran Universitas Indonesia, (2012).
Mudd, T. W., Khalid, M. & Guddati, A. K., Cardiotoxicity of chemotherapy and targeted agents. Am J Cancer Res, 11(4): 1132–1147 (2021).
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. & Baradaran, B., The Different Mechanisms ofCancer Drug Resistance: A Brief Review. Adv. Pharm. Bull., 7(3): 339–348 (2017).
Burmistrova, O., Marrero, M. T., Estévez, S., Welsch, I., Brouard, I., Quintana, J. & Estévez, F., Synthesis and effects on cell viability of flavonols and 3-methyl ether derivatives on human leukemia cells. Eur. J. Med. Chem., 84: 30–41 (2014).
Ikhtiarudin, I., Frimayanti, N., Teruna, H. Y. & Zamri, A., Microwave-assisted synthesis, molecular docking study and in vitro evaluation of halogen-substituted flavonols against P388 murine leukemia cells. Appl. Sci. Technology, 1(1): 375–381 (2017).
Collins-Burow, B. M., Burow, M. E., Duong, B. N. & McLachlan, J. A., Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr. Cancer, 38(2): 229–244 (2000).
Collins-Burow, B. M., Antoon, J. W., Frigo, D. E., Elliott, S., Weldon, C. B., Boue, S. M., Beckman, B. S., et al., Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J. Steroid Biochem. Mol. Biol., 132(1–2): 186–193 (2012).
Resende, F. A., de Oliveira, A. P. S., de Camargo, M. S., Vilegas, W. & Varanda, E. A., Evaluation of the estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/BUS cell proliferation assay. PLoS One, 8(10): e74881 (2013).
Ward, H. A. & Kuhnle, G. G. ., Phytoestrogen consumption and association with breast, prostate and colorectal cancer in EPIC Norfolk. Arch. Biochem. Biophys., 501(1): 170–175 (2010).
Sharma, D., Kumar, S. & Narasimhan, B., Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chem. Cent. J., 12: 107 (2018).
Maruyama, K., Nakamura, M., Tomoshige, S., Sugita, K., Makishima, M., Hashimoto, Y. & Ishikawa, M., Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERα-selective antagonist. Bioorg. Med. Chem. Lett., 23: 4031–4036 (2013).
Zeiller, J.-J., Berthelon, J.-J., Quentin, Y. & Depin, J.-C., Benzopyran and benzothiopyran derivatives as PAF antagonists. Organ. Mond. La Propr. Intellect. Bur. Int., WO19940014: (1994).
Wadood, A., Ahmed, N., Shah, L., Ahmad, A., Hassan, H. & Shams, S., In-silico drug design : An approach which revolutionarised the drug discovery process. OA Drug Des. Deliv., 1(1): 1–4 (2013).
Ikhtiarudin, I., Agistia, N., Frimayanti, N., Mora, E., Dona, R., Rahmawati, R. D. & Zamri, A., Sintesis, karakterisasi struktur, dan kajian molekular docking senyawa 4’-metoksi flavonol sebagai inhibitor main protease ( M Pro ) SARS-CoV-2. MFF, 26(April): 8–14 (2022).
Habibi, R., Herfindo, N., Hendra, R., Teruna, H. Y. & Zamri, A., Synthesis and molecular docking study of 1-(3-chloropropyl )-3,5-Bis((E)-4-methoxybenzylidene) piperidin-4-one as dengue virus type 2 (DEN2)NS2B/NS3 protease inhibitor candidate. PCPR, 5(1): 14–22 (2020).
Ikhtiarudin, I., Dona, R., Frimayanti, N., Utami, R., Susanti, E., Mentari, M., Nurmaida, N., et al., (E)-4-(3-(3-(4-methoxyphenyl)acryloyl)phenoxy)butyl 2-Hydroxybenzoate. Molbank, 2021(1): M1195 (2021).
Puranik, N. V., Srivastava, P., Bhatt, G., John Mary, D. J. S., Limaye, A. M. & Sivaraman, J., Determination, and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modeling approach. Sci. Rep., 9(1): 1–12 (2019).
Mirza, D. M., Ma’arif, B., Purbosari, I., Hardjono, S. & Agil, M., Prediksi aktivitas fitoestrogenik senyawa golongan flavonoid terhadap receptor estrogen α (ER- α) dengan pendekatan In Silico. J. Sains dan Kes, 3(4): 512–519 (2021).
Markham, K. R., Cara Mengidentifikasi Flavonoid. Institut Teknologi Bandung, (1998).
Mabry, T.J., Markham, K.R., Thomas, M. ., The Ultraviolet Spectra of Flavones and Flavonols. In: The Systematic Identification of Flavonoids. Springer, (1970).
Suhartati, T., Dasar-dasar spektrofotometri UV-Vis dan spektrometri massa untuk penentuan struktur senyawa organik. CV. Anugrah Utama Raharja, (2017).
Nandiyanto, A. B. D., Oktiani, R. & Ragadhita, R., How to read and interpret FTIR spectroscope of organic material. Indones. J. Sci. Technol., 4(1): 97–118 (2019).
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A. & Greene, G. L., The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95(7): 927–937 (1998).
Purwani, S., Nahar, J., Zulfikar, Z., Nurlelasari, N. & Mayanti, T., Molecular docking on kokosanolide A and C for anticancer activity against human breast cancer cell MCF-7. JKV, 7(1): 52–57 (2021).
Sari, I. W., Junaidin, J. & Pratiwi, D., Studi molekular docking senyawa flavonoid herba kumis kucing (Orthosiphon stamineus B.) pada reseptor α-glukosidase sebagai antidiabetes tipe 2. J. Farmagazine, 7(2): 54–60 (2020).
Prasetiawati, R., Zamri, A., Barliana, M. I. & Muchtaridi, M., In silico predictive for modification of chalcone with pyrazole derivatives as a novel therapeutic compound for targeted breast cancer treatment. JAPS, 9(02): 20–28 (2019).
Aditama, A. P. R., Ma’arif, B., Mirza, D. M., Laswati, H. & Agil, M., In Vitro and in silico analysis on the bone formation activity of n-hexane fraction of semanggi (Marsilea crenata Presl.). Sys Rev Pharm, 11(11): 837–849 (2020).
Muchtaridi, M., Syahidah, H. N., Subarnas, A., Yusuf, M., Bryant, S. D. & Langer, T., Molecular docking and 3D-pharmacophore modeling to study the interactions of chalcone derivatives with estrogen receptor alpha. Pharmaceuticals, 10(81): 1–12
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Please find the rights and licenses in Jurnal Riset Kimia (J. Ris. Kim). By submitting the article/manuscript of the article, the author(s) agree with this policy. No specific document sign-off is required.
1. License
The use the article will be governed by the Creative Commons Attribution license as currently displayed on Creative Commons Attribution 4.0 International License.Â
2. Author(s)' Warranties
The author warrants that the article is original, written by stated author(s), has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author(s).
3. User Rights
Under the Creative Commons license, the journal permits users to copy, distribute, and display the material for any purpose. Users will also need to attribute authors and J. Ris. Kim on distributing works in the journal and other media of publications.
4. Rights of Authors
Authors retain all their rights to the published works, such as (but not limited to) the following rights;
- Copyright and other proprietary rights relating to the article, such as patent rights,
- The right to use the substance of the article in own future works, including lectures and books,
- The right to reproduce the article for own purposes,
- The right to self-archive the article,
- The right to enter into separate, additional contractual arrangements for the non-exclusive distribution of the article's published version (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
5. Co-Authorship
If the article was jointly prepared by more than one author, any authors submitting the manuscript warrants that he/she has been authorized by all co-authors to be agreed on this copyright and license notice (agreement) on their behalf, and agrees to inform his/her co-authors of the terms of this policy. J. Ris. Kim will not be held liable for anything that may arise due to the author(s) internal dispute. J. Ris. Kim will only communicate with the corresponding author.
![](https://i1.wp.com/www.internetgeography.net/wp-content/uploads/2017/11/word-doc-icon.png"){kind=icon}
